Teva and Biolojic enter antibody license deal

Generics giant Teva Pharmaceutical Industries (NYSE and TASE: TEVA) and fellow Israel-based artificial intelligence (AI) focused biotech Biolojic Design have signed a license agreement to develop a potential novel antibody-based therapy for the treatment of atopic dermatitis and asthma.

Teva says this agreement supports one of the key pillars in its Pivot to Growth strategy announced in May 2023, to step up innovation, by enhancing the company’s early-stage pipeline organically and through strategic partnerships.

In return for Teva receiving exclusive rights to develop, manufacture and commercialize BD9 worldwide, Biolojic will receive an undisclosed upfront amount, and will be eligible for subsequent milestone payments over the next several years, based on the achievement of certain pre-clinical, clinical, regulatory, and commercial milestones. Biolojic is also eligible to receive tiered royalties in the mid-single to low-double digit on product sales should Teva successfully commercialize a therapy.